Tenaya Therapeutics, Inc. has appointed Eric Hyllengren as its new Chief Financial Officer (CFO), effective July 13, 2026. Mr. Hyllengren will also serve as the company's Principal Financial Officer and Principal Accounting Officer. He brings over two decades of experience in biotechnology finance, capital markets, and corporate strategy. His prior roles include CFO at Zura Bio Ltd. and CFO and COO at Atara Biotherapeutics. Mr. Hyllengren will receive an annual base salary of $490,000 and is eligible for a target annual bonus of 40% of his base salary. He will be granted an option to purchase 1,650,000 shares of the company's common stock, vesting over time. Faraz Ali, CEO, will transition from interim Principal Financial Officer, and Tomohiro Higa, Senior Vice President, Finance, will transition from acting interim Principal Accounting Officer. Mr. Higa will retire in the third quarter of 2026 but will remain as a consultant to ensure a smooth transition.